Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: A non-inferiority trial

Japanese Journal of Clinical Oncology

Volumn 39, Issue 7, 2009, Pages 443-448

  Yonemura, Masahito ^a   Katsumata, Noriyuki ^b   Hashimoto, Hironobu ^a   Satake, Shoko ^a   Kaneko, Masayuki ^b   Kobayashi, Yuka ^a   Takashima, Atsuo ^b   Kato, Yasuhisa ^a   Takeuchi, Masahiro ^b   Fujiwara, Yasuhiro ^b   Yamamoto, Hiroshi ^a   Hojo, Taisuke ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

Antiemetic; Granisetron; Non inferiority trial; Serotonin antagonist; Vomiting

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GRANISETRON; IRINOTECAN; PACLITAXEL; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT;

ANOREXIA; ARTICLE; BREAST CANCER; CANCER OF UNKNOWN PRIMARY SITE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; FEMALE; GYNECOLOGIC CANCER; HUMAN; MAJOR CLINICAL STUDY; MALAISE; MALE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA AND VOMITING; OVARY CANCER; RANDOMIZED CONTROLLED TRIAL; SARCOMA; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SYNCOPE; UROGENITAL TRACT TUMOR; UTERINE CERVIX CANCER; ADULT; AGED; CANCER STAGING; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; NAUSEA; NEOPLASM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANISETRON; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NAUSEA; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS; SINGLE-BLIND METHOD; SURVIVAL RATE; TREATMENT OUTCOME; VOMITING; YOUNG ADULT;

EID: 67649908837     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp036     Document Type: Article

References (16)

1. Mitchell EP. Gastrointestinal toxicity of chemotherapeutic agents. Semin Oncol 1992;19:566-79.
2. Richardson JL, Marks G, Levine A. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol 1988;6:1746-52.
3. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-9.
4. Jantunen IT, Kataja VV, Muhonen TT. An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer 1997;33:66-74.
5. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. J Clin Oncol 1999;17:2971-94.
6. NCCN Clinical Practice Guidelines in Oncology: Antiemesis, Ver1. 2005, http://www.nccn.org/professionals/physician_gls/PDF/ antiemesis-Japanese.pdf.
7. Herrstedt J, Aapro MS, Roila F, Kataja VV. ESMO Minimum Clinical Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV). Ann Oncol 2005;16(Suppl 1):i77-9.
8. Furue H, Oota K, Taguchi T, Niitani H. Clinical evaluation of granisetron against nausea and vomiting induced by anticancer drugs (I). Rinsho Iyaku 1990;6:49-61 (in Japanese).
9. Japanese translation of common terminology criteria for adverse events (CTCAE), and instructions and guideline. Int J Clin Oncol 2004;9(Suppl 3):1-82 (in Japanese).
10. The Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995;332:1-5.
11. Soucop M. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. Eur J Cancer 1990;26:S15-9.
12. Smith IE. A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. Eur J cancer 1990;26:S19-23.
13. Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer R, Fitts D. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 1994;12:2204-10.
14. Riviere A. Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 1994;69:967-71.
15. Navari RM, Gandara DR, Hesketh PJ, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995;13:1242-8.
16. Aapro MS, Thuerlimann B, Sessa C, De Pree C, Bernhard J, Maibach R. A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Ann Oncol 2003;14:291-7.